Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AWK$142.08-0.67(-0.47%)American Water Contributes Expertise at California Water Association 2026 Summit American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., will join important conversations and contribute...[9:03:00 AM ET]TFC$48.91+0.47(+0.97%)Truist names Alex Bartlett regional president for Greater Washington and Maryland Truist Financial Corporation (NYSE: TFC) today announced Alex Bartlett has been named regional president for Greater Washington and Maryland. A...[9:03:00 AM ET]MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.53-0.10(-0.48%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.23+0.11(+9.82%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]ATYR$0.12-0.03(-18.77%)aTyr Pharma Announces One-for-40 Reverse Stock Split[9:00:00 AM ET]KD$14.70+0.02(+0.14%)Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today unveiled a new Cyber Defense Operations Center in...[9:00:00 AM ET]DVN$51.27-0.37(-0.72%)NEQ Operating Strengthens Leadership Team to Support Next Phase of Growth[9:00:00 AM ET]

KNSA · NASDAQ

Kiniksa Pharmaceuticals, Ltd.

$83.55 +10.70 (+14.69%)

Company overview

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for giant cell arteritis; Vixarelinab, a monoclonal antibody in Phase 2a clinical trial for prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40-CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$6.5B
Employees
315
Headquarters
Hamilton
Website
kiniksa.com
CEO
Sanj K. Patel
Listed
May 25, 2018
P/E
85.26
Dividend yield
0.00%

Company financials

Revenue
$754M
Gross profit
$412M
Operating income
$93.2M
EBITDA
$102M
Net income
$73.1M
EPS
$0.98
Total assets
$825M
Total debt
$9M
Gross margin
54.63%
Net margin
9.69%
Earnings yield
1.17%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

40.2651.6363.0074.3785.74
KNSA 1D NASDAQ O75.13H75.57L70.70C72.85-3.88 (-5.06%)Vol371.29K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
KNSAKiniksa Pharmaceuticals, Ltd. Press release Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution GlobeNewswire
KNSAKiniksa Pharmaceuticals, Ltd. Press release Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026 GlobeNewswire
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM) Defense World
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why Zacks Investment Research
KNSAKiniksa Pharmaceuticals, Ltd. Press release Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference GlobeNewswire
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 MarketBeat
KNSAKiniksa Pharmaceuticals, Ltd. Press release Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference GlobeNewsWire
KNSAKiniksa Pharmaceuticals, Ltd. Stock news KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook Zacks Investment Research
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why Zacks Investment Research
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why Zacks Investment Research
KNSAKiniksa Pharmaceuticals, Ltd. Stock news A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41 GuruFocus
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences Globe News Wire
KNSAKiniksa Pharmaceuticals, Ltd. Press release Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewsWire
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation Seeking Alpha
BKNG Stock news Breakfast News: Enphase Dips As Solar Demand Dims Fool - Investing News
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today The Motley Fool
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript Seeking Alpha
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates Zacks Investment Research
KNSAKiniksa Pharmaceuticals, Ltd. Stock news Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution Globe News Wire
KNSAKiniksa Pharmaceuticals, Ltd. Press release Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution GlobeNewsWire
See more
FAQ

Questions about Kiniksa Pharmaceuticals, Ltd.

What does Kiniksa Pharmaceuticals, Ltd. do?
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for giant cell arteritis; Vixarelinab, a monoclonal antibody in Phase 2a clinical trial for prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40-CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
What is KNSA's market cap?
Kiniksa Pharmaceuticals, Ltd. (KNSA) is a listed stock with a live quote. The latest market cap on this page is $6.5B.
Where is Kiniksa Pharmaceuticals, Ltd. headquartered?
Kiniksa Pharmaceuticals, Ltd. is headquartered in Hamilton.
How do I get KNSA news from the API?
Call GET /v1/news?tickers=KNSA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does KNSA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for KNSA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the KNSA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs